期刊文献+

二膦酸盐药物治疗乳腺癌骨转移发生颌骨坏死的临床特点 被引量:13

Clinical features of osteonecrosis of jaws after bisphosphonates therapy for bone metastasis of breast cancer
下载PDF
导出
摘要 目的:乳腺癌是女性最常见的恶性肿瘤之一,骨转移在该类患者中较为常见。二膦酸盐药物是预防和控制恶性肿瘤骨转移的一线化学治疗药物,长期应用可以发生颌骨坏死。本研究旨在深入了解应用二膦酸盐药物治疗乳腺癌骨转移后患者发生颌骨坏死的临床特点。方法:回顾分析自2011年1月至2015年8月于北京大学口腔医院就诊并明确诊断为二膦酸盐颌骨坏死的患者,筛选出其中的乳腺癌患者,分析其临床症状、影像学特征及治疗情况。结果:共纳入14例乳腺癌患者,平均年龄60.21岁,平均罹患肿瘤时间9.77年,平均出现骨转移时间为5.67年,平均应用二膦酸盐药物的时间为3.29年。患者均无系统应用激素治疗史,无糖尿病史。9例患者曾经拔牙,口腔内颌骨坏死症状的平均时间为8.58个月,发生在下颌骨者10例,上颌骨3例,上、下颌骨1例。10例经手术治疗的患者中,3例治愈,6例好转,而4例经保守治疗的患者中2例临床症状明显加重。结论:乳腺癌患者自开始应用二膦酸盐药物至发生颌骨坏死的用药时间较长,多数患者没有糖尿病及应用激素治疗史。拔牙本身与颌骨坏死的严重程度没有直接关系,下颌骨是最常受累的部位,手术治疗可以在一定程度上缓解乳腺癌患者发生二膦酸盐相关性颌骨坏死的临床症状。 Objective:To understand the clinical Mates use for therapy of breast cancer patients with features of osteonecrosis of the jaw after bisphospho- bone metastasis. Methods: The cases diagnosed as bisphosphonates-related osteonecrosis of the jaws (BRONJ) were retrospectively analyzed from January 2011 to August 2015 in the Peking University School and Hospital of Stomatology, and those breast cancer patients with bone metastasis were selected. The clinical symptoms, imaging characteristics and treatment results were summarized. Results: A total of 14 cases of breast cancer patients with bone me- tastasis were selected, with an average age of 60.21 years. The average time of suffering from breast cancer was 9.77 years, and the average time of bone metastasis and bisphosphonates drugs use was 5.67 and 3.29 years individually. There was no patient with systemic application history of hormone therapy, and no history of diabetes. There were 9 patients with tooth extractions history, and the mean time of bone necrosis symptoms was 8.58 months. There were 10 cases with bone necrosis occurring on mandi- ble, 3 cases on maxilla, and one case with both upper and lower jaws involved. Among the 10 patients with surgical treatment, there were 3 cases cured, and 6 cases improved. However, the clinical symp- toms of 2 cases with conservative treatment were significantly aggravated. Conclusion: The medication time between the bisphosphonates use beginning and the occurrence of BRONJ is relatively long. The his- tory of diabetes and long-time hormone use did not exist in this group. Tooth extraction itself does not de- termine the severity of BRONJ. Mandible is the most common site involved by BRONJ. Surgical treatment can alleviate the clinical symptoms of BRONJ with breast cancer to some extent.
出处 《北京大学学报(医学版)》 CAS CSCD 北大核心 2016年第1期80-83,共4页 Journal of Peking University:Health Sciences
基金 北京大学口腔医院青年科研基金项目(PKUSS20140103)资助~~
关键词 二膦酸盐类 骨坏死 肿瘤转移 Diphosphonates Osteonecrosis Jaw Neoplasm metastasis
  • 相关文献

参考文献10

  • 1乳腺癌骨转移和骨相关疾病临床诊疗专家共识(2008版)[J].中华肿瘤杂志,2009,31(2):156-159. 被引量:33
  • 2郭玉兴,王佃灿,安金刚,彭歆,蔡志刚,郭传瑸.二膦酸盐颌骨骨髓炎24例临床特点分析[J].中华口腔医学杂志,2014,49(9):517-520. 被引量:18
  • 3Coleman RE. Metastatic bone disease: clinical features, patho- physiology and treatment strategies [ J]. Cancer Treat Rev, 2001, 27(3) : 165 -176.
  • 4Wutzl A, Biedermann E, Wanschitz F, et al. Treatment results of bisphosphonate-related osteonecrosis of the jaws [ J]. Head Neck, 2008, 30(9) : 1224 -1230.
  • 5Holzinger D, Seemann R, Klug C, et al. Long-term success of surgery in bisphosphonate-related osteonecrosis of the jaws (BRONJs) [J]. Oral Oncol, 2013, 49(1): 66-70.
  • 6Hewitt C, Farah CS. Bisphosphonate-related osteonecrosis of the jaws: a comprehensive review [J]. J Oral Pathol Med, 2007, 36 (6) : 319 -328.
  • 7Kuhl S, Walter C, Acham S, et al. Bisphosphonate-related osteo- necrosis of the jaws: a review [J]. Oral Onco|, 2012, 48(10) : 938 - 947.
  • 8McClung M, Miller P, Recknor C, et al. Zoledronie acid for the prevention of bone loss in postmenopausal women with low bone mass : a randomized controlled trim [ J ]. Obstet Gyneeol, 2009, 114(5) : 999 - 1007.
  • 9Zhang Q, Atsuta I, Liu S, et al. IL-17-mediated M1/M2 macro- phage alteration contr/butes to pathogenesis of bisphosphonate-re- lated osteonecrosis of the jaws [J]. Clin Cancer Res, 2013, 19 (12) : 3176 -3188.
  • 10郭玉兴,王佃灿,王洋,彭歆,郭传瑸,毛驰.血管化腓骨瓣修复二膦酸盐颌骨骨坏死导致的下颌骨缺损:病例报告及文献复习[J].中国口腔颌面外科杂志,2015,13(5):474-477. 被引量:4

二级参考文献51

  • 1Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev, 2001, 27:165-176.
  • 2Johnson JR, Williams G, Pazdur R, et al. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol, 2003, 21 : 1404-1411.
  • 3Kinnane N. Burden of bone disease. Eur J Oncol Nuts, 2007, 11 Suppl 2 : S28-31.
  • 4Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med, 2005, 35:84-99.
  • 5Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol, 2007, 25: 1423-1436.
  • 6Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oneology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oneol, 2003, 21:4042-4057.
  • 7Weitnnan R, Sauter N, Eriksen EF, et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006. Crit Rev Oncol Hematol, 2007, 62:148-152.
  • 8Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J CIin Oncol, 2005, 23:4925-4935.
  • 9Brown JE, Thomson CS, Ellis SP, et al. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer, 2003, 89:2031-2037.
  • 10Clemons MJ, Dranitsaris G, Ooi WS, et al. Phase Ⅱ trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oneol, 2006, 24:4895-4900.

共引文献50

同被引文献123

  • 1骨质疏松及骨矿盐疾病诊疗指南(讨论稿)[J].国际内分泌代谢杂志,2006,26(4):291-298. 被引量:47
  • 2蔡德山.钙制剂“自强不息”[N].医药经济报.2007-02-05(3).
  • 3陆再英,钟南山.内科学(第7版)[M].人民卫生出版社,2008,717.
  • 4Cafro AM, Barbarano L, Nosari AM, et aL Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphospho- hates : definition and management of the risk related to zoledron- ic acid [ J ]. Clin Lymphoma Myeloma, 2008,8 ( 2 ) : 111- 116.
  • 5Fedele S, Bedogni G, Scoletta M, et al. Up to a quarter of pa- tients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed[J]. Br J Oral Maxillofac Surg, 2015, 53(1): 13-17.
  • 6Ruggiero SL, Dodson TB, Assael LA, et al. American Associa- tion of Oral and Maxillofacial Surgeons position paper on bisphos- phonate-related osteonecrosis of the jaw- 2009 update [Jl. Aust Endod J, 2009,35 (3) : 119-130.
  • 7Ruggiero S, Gralow J, Marx RE, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer[J ]. J Oncol Pract, 2006,2/1 ) :7-14.
  • 8Wutzl A, Biedermann E, Wanschitz F, et al. Treatment results of bisphosphonate-relaed osteonecrosis of the jaws [J]. Head Neck, 2008,30(9) : 1224-1230.
  • 9Carlson ER, Basile JD. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws [ J ]. J Oral Maxillofac Surg, 2009,67 (5 Suppl ) : 85-95.
  • 10Marx RE, Cillo JJ, Ulloa JJ. Oral bisphosph0nate-induced os-teonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment [J]. J Oral Maxillofac Surg, 2007,65(12) :2397-2410.

引证文献13

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部